MAP1LC3A and cancer: Whereasin vivo results indicated that the chemotherapeutic drug’sefficiency was greatly increased as demonstrated by a reduction intumor sizes.273 In our current researchgroup work, a “smart” nanocarrier has been developedas the carrier of LC3 siRNA to deliver combination of DOX and LC3siRNA for cancer therapy in TNBC.